Drug Profile


Alternative Names: Anti-VAP-1 monoclonal antibody fully human; BTT-1023; Fully human anti-VAP-1 monoclonal antibody; Fully human anti-vascular adhesion protein 1 monoclonal antibody; SI-3106

Latest Information Update: 02 Mar 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biotie Therapies Corp.
  • Developer Acorda Therapeutics; Biotie Therapies Corp.; Seikagaku Corporation
  • Class Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action AOC3 protein inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary sclerosing cholangitis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Primary sclerosing cholangitis
  • No development reported Inflammation; Plaque psoriasis; Rheumatoid arthritis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 01 Feb 2017 Biotie in collaboration with the University of Birmingham complete a phase II trial in in Primary sclerosing cholangitis in United Kingdom (IV) (NCT02239211; EudraCT2014-002393-37; ISRCTN11233255)
  • 26 Aug 2016 BTT 1023 receives Orphan Drug status for Primary sclerosing cholangitis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top